Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06284590
Title Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients (INTACT/MeRCI)
Acronym INTACT/MeRCI
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Philogen S.p.A.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.